Global Injectables(8) 3% 11% 6%
Infusion Systems 4% 6% 5%
Anesthesia(9) 42% 57% 46%
Other(10) (20%) 40% 10%
----------------------------------
Total Medication Delivery 8% 13% 10%
----------------------------------
Renal
PD Therapy 3% 11% 10%
HD Therapy (4%) 4% 2%
----------------------------------
Total Renal 1% 9% 8%
Baxter excluding Transfusion
Therapies 12% 10% 11%
----------------------------------
Transfusion Therapies(11) (48%) (79%) (64%)
----------------------------------
TOTAL BAXTER 9% 7% 8%
==================================
(1) Prior year data has been reclassified to reflect the changes that
are described in Notes 2, 5, 6, 8, 9 and 11 below.
(2) Includes sales of recombinant FVIII products (ADVATE and
RECOMBINATE). Sales of recombinant FIX (BeneFIX) were previously
reported in Recombinants and are now reported in Other, as detailed
below.
(3) Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA),
albumin, and certain other plasma-based products.
(4) Previously referred to as BioSurgery.
(5) Principally includes vaccines, sales of plasma to third parties, and
recombinant FIX (BeneFIX). Sales of recombinant FIX were
'/>"/>
| SOURCE Baxter International Inc. Copyright©2007 PR Newswire. All rights reserved |